BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 10, 2006
View Archived Issues
Shire recaps year's successes
Read More
Incyte makes considerable progress in fourth quarter
Read More
Enrollment completed in first of two phase III studies of AI-700
Read More
Digna Biotech and Biotherapix to develop treatment for pulmonary fibrosis
Read More
Novo Nordisk reinitiates phase III program for AERx iDMS
Read More
Enrollment completed in phase I study of AdPEDF gene therapy
Read More
Enrollment open in phase I study of BSI-201 for advanced malignancies
Read More
Phase II study of DP-b99 in acute stroke cleared to continue
Read More
Baxter opens phase II adult stem cell therapy trial for chronic myocardial ischemia
Read More
Juvaris awarded SBIR grant for HIV vaccine development
Read More
Quigley files IND for clinical trials of QR-333 in diabetic peripheral neuropathy
Read More
Positive results for Zegerid in nocturnal acid breakthrough
Read More
Nonapprovable letter for Vadova
Read More
Reveromycin A shows potential for osteoporosis
Read More
Kyorin's antidiabetic agent KRP-104 begins phase I
Read More
Shionogi and Galderma reach initial sales agreement for adapalene gel
Read More
N-Acetylcysteine: an antioxidant and MMP inhibitor for oral cancer
Read More
European approval for Remicade for ulcerative colitis
Read More
EM-011: Potential oral treatment of drug-resistant lymphomas
Read More
Novel agents imparted for the treatment of inflammatory disorders
Read More
Recent patents impart novel agents for obesity and lipoprotein disorders
Read More
Novel analgesic agents disclosed in recent patent literature
Read More
Promising results from phase I and II studies in prostate cancer
Read More
Preliminary clinical data on efalizumab for the treatment of oral lichen planus reported
Read More
Kaken reports preclinical data on its novel leukotriene/thromboxane dual inhibitor KP-496
Read More
New preclinical data on Chinese herbal medicine formula presented
Read More
